http://medconferencestoday.com

Breaking Medical Conference News...

Health Disparities Field Experience At Mayo Clinic

As part of its mission to train the next generation of physicians and scientists, the Mayo Clinic Center for Translational Science Activities (CTSA) offers the Health Disparities Field Experience, a unique course through Mayo Graduate School.

Training Program To Prevent Groundwater Poisoning In India

A team of scientists at Queen's University has been chosen to lead a top research and training programme to prevent groundwater poisoning in India. More than 70 million people in Eastern India and Bangladesh experience involuntary exposure to the poisonous chemical arsenic, from consuming water and rice. This includes farmers who have to use contaminated groundwater for minor irrigation schemes.

Review Of The Effect Of European Working Time Directive On Junior Doctor Training

A review into the quality of training for junior doctors in the light of the implementation of the European Working Time Directive was announced by Health Secretary Alan Johnson today. The review will consider the concerns raised by some professionals that the introduction of a 48-hour working week may have a detrimental effect on junior doctors' training, particularly on the training they receive while at work.

The Best CROs bring a “big picture” Perspective

The key benefit of having a full service CRO is their ability to asses and expand risk management and to encompass a broader range of risk issues. The best CROS tend to have the communication skills required to influence the board, managers and employees responsible for making the day to day ...
(613) 686-5745 Cerepotec Pharmalef

Namibia's Education Ministry Launches HIV/AIDS Booster Packs For Teachers, Staff

Namibia's Ministry of Education has made immune system booster packs part of its efforts to mitigate the effects of HIV/AIDS on the education sector in the country, the Namibian/AllAfrica.com reports.

Stanford Medical School To Provide Online Disclosure Of Faculty's Consulting Activities

The Stanford University School of Medicine announced that it would be posting on its Web site the medical- and research-related consulting activities for some 1,200 physicians and faculty affiliated with the medical school. The new policy is slated to go into effect later this year and will make widely available to the public information that clinicians and researchers already disclose annually as part of the school's procedures to manage conflicts of interest.

National Primary Care Week Addresses Critical Shortage Of Physicians In United States

Hundreds of health profession students will celebrate the 11th Annual National Primary Care Week (NPCW), October 19-23, 2009. NPCW, a project of the American Medical Student Association (AMSA), highlights the significance of primary care and provides an interactive environment for discussing the importance of primary care in today's health care system. "The shortage of primary care physicians in the United States is tragic," says Lala Yogendran, AMSA NPCW coordinator.

What the Title of Home-based Clinical Research Associate Really Means

The title of Clinical Research Associate is deceiving to some degree. Many people think of “associate” as a secondary low paying job. “Clinical Monitor” is a title that better describes what CRA job entails. A clinical research associate does not, in fact, assist anyone; the associate ...
(613) 686-5745 Cerepotec Pharmalef

Australian Medical Students Association: Medical Training Solutions For National Doctor Shortage

The Australian Medical Students' Association (AMSA) has reiterated calls for State and Federal Governments to urgently address the shortage of clinical training places available to medical students and junior doctors. The number of medical students graduating annually in Australia is expected to increase almost three fold in 10 years, from 1200 in 2002 to 3300 in 2012.

Concordia University To Build Innovative Centre For Health Research And Training

Judith Woodsworth, President and Vice-Chancellor of Concordia University is delighted to announce the creation of the PERFORM Research Centre. The acronym PERFORM stands for Prevention, Evaluation, Rehabilitation, FORMation. The Centre will become a reality thanks to a grant of $34,972,317 from the Federal and Provincial Governments, through the Knowledge Infrastructure Program.

American Nurses Association Releases 2nd Edition Of Teaching IOM: Implications Of The Institute Of Medicine Reports For Nursing Education

The American Nurses Association (ANA) is pleased to announce the release of its second edition of Teaching IOM: Implications of the Institute of Medicine Reports for Nursing Education on September 15. The second edition of Teaching IOM continues the authors' dialogue with nursing that began with the first edition.

Understanding the Importance of ICH GCP is Vital to the Continued Safety of Clinical Patients.

Several Kriger www.krigerinternational.com course sessions are dedicated to understanding concepts and principles that have helped mold the industry into what it is today. This gives each student the opportunity to understand how the industry is progressing, so that when they take their place ...
(613) 686-5745 Cerepotec Pharmalef

GMC Conducts Major Review Of Medical Schools Guidance, UK

Doctors, medical students, health employers and patient groups have the opportunity to influence the GMC's guidance for medical schools, at a consultative conference being held today, 2 March. The draft guidance, Tomorrow's Doctors, will set out the standards medical students will be expected to meet before they graduate. The consultation runs until 27 March.

European Union Of Medical Students Gets MEPs Support On Bowis Report Amendments

In the framework of the discussions in view of the first reading on the draft Directive on Patients' Rights in Cross-Border Healthcare the UEMS (European Union of Medical Students) is pleased to report it has gained support from eminent Members of the European Parliament on its proposals for further amending the Report drafted by John Bowis MEP.

GPs Boost Cancer Screening Skills, Australia

The Royal Australian College of General Practitioners (RACGP) has launched a new online learning activity designed to support general practitioners in boosting their knowledge about the latest approaches to the early detection of common types of cancer including breast cancer, cervical cancer, melanoma, lung cancer, ovarian cancer, prostate cancer and bowel cancer.

Clinical Research Professionals are Still in Demand despite the World Economic Crisis

Despite the world economic crisis, the clinical research field is currently expanding faster than the introduction of newly qualified professionals that inevitably creates a demand. Most people are under the impression that the barriers to enter this industry are extremely difficult to ...
(613) 686-5745 Cerepotec Pharmalef

New Doctors, Teaching Physicians Disagree About Essential Medical Procedures To Learn

Physicians teaching at medical schools and doctors who have just completed their first year out of medical school disagree about which procedures are necessary to learn before graduating, according to a new survey done by researchers at Wake Forest University School of Medicine. Participating physicians were asked to rate 31 basic clinical procedures from throat culture to spinal tap based on their importance in the first year after graduation from medical school.

International Health Research Gets Boost With NIH Grant To Create Bioethics Master's Degrees At Indiana And Moi Universities, USA

A new partnership between the Indiana University and Kenya's Moi University will develop master's degrees at both universities that focus on ethical issues in international health research. The program, funded with a $940,000 award from the National Institutes of Health Fogarty International Center, will create the Indiana University-Moi University Academic Research Ethics Partnership (IU-Moi AREP).

University Of Wisconsin-Madison Tackles Neglected Realm Of Training For Science Professors In Training

U.S. science and engineering students emerge from graduate school exquisitely trained to carry out research. Yet when it comes to the other major activity they'll engage in as professors - teaching - they're usually left to their own devices. That's now beginning to change, thanks to work at the University of Wisconsin-Madison. In the Nov.

The Birth of the Profession of Clinical Research Associate

According to the ICH Good Clinical Practice Guidelines, clinical research should be monitored by professionals—Clinical Research Associates, also known as Clinical Monitors. We asked Bruce Kriger, CEO of Kriger Research Group International www.kriger.com , leading training institution and ...
(613) 686-5745 Cerepotec Pharmalef

American Medical Student Association Applauds Increase To National Health Service Corps

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, applauds the U.S. House of Representatives for passing the Health Centers Renewal Act (H.R. 1343), which reauthorizes the National Health Service Corps (NHSC) and increases its funding to over $185 million, an increase of more than 30 percent.

New Way Of Gauging Professional Behavior In Medical Students

A new way of assessing professionalism among medical students could help to make better doctors, a new research study suggests. A score given to medical students, called the Conscientiousness Index, can detect behaviours which may need investigation at an early stage, allowing targeted support to be given to ultimately make for better doctors, according to the Durham University study.

Patient Societies From Armenia, Austria, Bulgaria, Hungary And Singapore Recognized For Their Innovative Projects

While awareness of osteoporosis among the public and health professionals is growing, there is still work to be done to ensure that doctors and other health professionals are adequately prepared to advise patients on the best possible care for osteoporosis.

Cereprotex displayed a significant anti-edema effect in a model of closed head injury.

Cereprotex displayed a significant anti-edema effect in a model of closed head injury. It significant decreases in the degree of edema developed after injury was found following treatment postponed one hour after traumatic injury. About 35% less water accumulated in the traumatized hemisphere ...
(613) 686-5745 Cerepotec Pharmalef

Residency Training Study Sees Greater Benefit From Time In The Clinic

A new approach to internal medicine residency training could improve patient care and physician-patient relationships, according to a University of Cincinnati (UC) study. Eric Warm, MD, associate professor of medicine and lead investigator of the study, says research showed residents who spent increased time in outpatient settings as opposed to the hospital delivered a higher quality of care and had more satisfaction in their duties.

Students Showcase Ageing Research, Australian National University

Could insect vision help older drivers to stay on the road longer and safer? That will be one of the questions addressed at the 2008 Intergenerational Forum on Ageing Research to be held tomorrow at The Australian National University. The forum has been organised by PhD students working on issues relevant to ageing, with the aim of bringing together and involving community and government organisations and local older people in their research.

AMSA Turns 50! Australia

Over the past few years, AMSA has been trawling through its archives trying to find out more about its past in an attempt to put together a comprehensive written and oral history of the organisation. The AMSA story is a fascinating one indeed - born from a small network of likeminded students in the 1960s, AMSA (like many in that decade) had a rather political adolescence in the 1970s, before maturing to the multifaceted advocacy and professional organisation it is today.

Kriger Research Group International provides clinical research services on a truly global scale.

Kriger Research Group International www.krigerclinical.com provides clinical research services for pharmaceutical and biotechnology product development from phase II through phase IV for US, Canadian, European and multinational pharmaceutical companies. KRGI is your way to high quality ...
(613) 686-5745 Cerepotec Pharmalef

Simulation Game Helps Students Learn Dental Implant Procedures

A realistic computer game will soon be used to help dental students worldwide learn and reinforce dental implant procedures. The Virtual Dental Implant Training Simulation Program is designed to help students in diagnostics, decision making and treatment protocols. It was designed by Medical College of Georgia School of Dentistry faculty and students and BreakAway, Ltd., a developer of game-based technology for training, experimentation and decision-making analysis.

Tree Of Life Award Received By Jefferson Doctor

Edith P. Mitchell, M.D., clinical professor, Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University and associate director of Diversity Programs for the Kimmel Cancer Center at Jefferson, was recently honored with a 'Tree of Life' award from The Wellness of You, a local nonprofit health education and resource organization. The Tree of Life award recognizes health professionals who are committed to making a difference in community health.

Millennium Development Goals Teaching Needed For Global Health, Australian Medical Students' Association

The Australian Medical Students' Association (AMSA) called for greater emphasis on teaching of the United Nations Millennium Development Goals in all Australian medical schools. Adopted by the UN in 2000, the Millennium Development Goals are a universally recognised framework that aims to advance global development and health by 2015 through eight key targets.

What the Title of Home-based Clinical Research Associate Really Means

The title of Clinical Research Associate is deceiving to some degree. Many people think of “associate” as a secondary low paying job. “Clinical Monitor” is a title that better describes what CRA job entails. A clinical research associate does not, in fact, assist anyone; the associate ...
(613) 686-5745 Cerepotec Pharmalef

Lancet Examines Uganda's Child-Health Volunteers

A Lancet World Report examines how a small group of village volunteers trained in basic health care are helping to improve the health of Ugandan children...

New Flexibility For Royal Australian College Of General Practitioners Exam Candidates

From January 2009 candidates for The Royal Australian College of General Practitioners (RACGP) Fellowship examination will be able to undertake the exam in a sequential way over time. "We recognise the changing needs of GPs who may need to work part time due to family circumstances and work life balance issues, the learning needs of registrars and the challenges for international medical graduates in gaining the experience required to work in Australia.

Med Schools Improve Conflict Of Interest Policies, But Widespread Problems Remain

According to the latest ratings of two watchdog groups, medical schools are "improving their conflict-of-interest policies to police their ties with drug and medical-device makers. But more than half the schools still have inadequate policies or no policies at all," the Wall Street Journal's Health Blog reports.

Kriger's Instructors Provide A Sound Foundation For Anyone Wishing To Seek A Meaningful Career In The Clinical And Biopharmaceutical Industry

As a drug makes its way through the different phases of pre-clinical and clinical trials in human testing, the public and the company can rest assured that their product has been thoroughly tested and that each progression through its development has been predicated upon safe, sound, efficient ...
(613) 686-5745 Cerepotec Pharmalef

Medical Students Urge Speaker Pelosi To Keep Her Promise

The American Medical Student Association (AMSA) urges Speaker Nancy Pelosi to keep her promise and allow a vote on a single payer substitution amendment to the House health care reform bill, to be introduced by Representative Anthony Weiner [D-NY].

Transparency In Medical Research And Education

U.S. Senators Mel Martinez (R-FL) and Herb Kohl (D-WI) of the Special Committee on Aging held a hearing to address the issue of transparency in physician-industry financial relationships. Among the hearing's topics were the industry's involvement in continuing medical education and its potential use as a method for promoting "off-label" prescribing.

Gallbladder Surgery Complications Reduced By Limiting Resident Surgeon's Work Hours

After resident physicians' work hours were limited to 80 hours each week, fewer patients undergoing gallbladder surgery at one major public teaching hospital suffered injuries to their bile ducts of other complications, according to an article released on September 15, 2008 in the Archives of Surgery, one of the JAMA/Archives journals.

EBRecruiters has a well established database of over 60,000 candidates all over the world

EBRecruiters www.ebrecruiters.com consultants have a wealth of knowledge and experience in Clinical Research, Data Management, Quality Assurance, Regulatory Affairs and all aspects of Information Technology and Office Support. EBRecruiters has a well established database of ...
(613) 686-5745 Cerepotec Pharmalef

Medical Students View The NHHRC Interim Report As A Healthy Start, Australia

The Australian Medical Students' Association (AMSA) congratulates the National Health and Hospital Reform Commission on its interim report released on Monday. The report highlighted the necessity of quality clinical education and guaranteed internship places to ensure the success of the future health workforce. The Commission further recognised that this outcome can only be accomplished through quality clinical placements, and providing quality teaching.

Families More Satisfied When Life Support Withdrawal Is Prolonged

According to an article published in the second October 2008 issue of the American Journal of Respiratory and Critical Care Medicine, doctors in intensive care units (ICUs) often withdraw life support systems over a prolonged period of time as they attempt to balance the difficult needs of their patients and the families of patients.

Biologists, Educators Hold Symposium And Special Workshop At National Biology Teachers Meeting In Memphis, Tenn.

On 16-17 October 2008, the American Institute of Biological Sciences (AIBS) and the National Evolutionary Synthesis Center (NESCent) will convene a special symposium and workshop for educators at the National Association of Biology Teachers (NABT) conference in Memphis, TN.

Understanding the Importance of ICH GCP is Vital to the Continued Safety of Clinical Patients.

Several Kriger www.krigerinternational.com course sessions are dedicated to understanding concepts and principles that have helped mold the industry into what it is today. This gives each student the opportunity to understand how the industry is progressing, so that when they take their place ...
(613) 686-5745 Cerepotec Pharmalef

Gender Equality Award For The Institute Of Cancer Research

The Institute of Cancer Research (ICR) is pleased to have been recognised for its focus on improving efforts to recruit, support and promote talented female scientists. The Athena SWAN awards are given to universities and research organisations that are committed to advancing the careers of women in science, engineering and technology. It recognises and celebrates organisations that strive to adopt good employment practice in this area.

US Must Enact Measures To Support The Role Of IMGs In US Health-care Delivery, Says ACP

In a new paper the American College of Physicians (ACP) says that because of the important place that international medical graduates (IMGs) "have and will continue to have" in the internal medicine workforce, the U.S. needs to enact measures that would support their role. The Role of International Medical Graduates in the U.S. Physician Workforce outlines recommendations that ACP feels would support that role.

With Medical School Enrollment Expanding For The First Time In 30 Years, Medical Leaders Urge Educators To Institute Curricula Reform Now

Calling this period "an unparalleled opportunity" for change, an influential group of medical leaders today urged the nation's medical schools to reform their educational model because it too often fails to give new physicians the right mix of competencies and experiences to practice medicine effectively. The call to action for education reform comes as medical schools are expanding their enrollments for the first time in 30 years to address a shortage of physicians in the United States.

Compliance in Developing countries is a balancing act

Clinproxy’s, www.clinproxy.com global spread continues to acknowledge to issues with regards to developing countries and the compliance required for clinical trials. Compliance is a balancing act between home-country regulations, international guidelines, and local rules and customs. ...
(613) 686-5745 Cerepotec Pharmalef

Obama Administration Announces More Than $327 Million In Recovery Act Funding For Science Research

U.S Department of Energy Secretary Steven Chu has announced that more than $327 million in new funding from the American Recovery and Reinvestment Act will go toward scientific research, instrumentation, and laboratory infrastructure projects. Ten of DOE's national laboratories in six states will be receiving funds, along with researchers at institutions of higher learning across the nation. "These new initiatives will help to create new jobs while allowing the U.S.

British Medical Association Responds To Government's Working Time Directive Training Review

Responding to Health Secretary Alan Johnson's announcement of a review on the impact of the European Working Time Directive on doctors' training, Dr Andy Thornley, Chair of the BMA's Junior Doctors Committee, said: "The NHS has had 11 years to prepare for the full implementation of the European Working Time Directive.

Dental Loupes For Students Offer From British Dental Association

Final-year dental students are to benefit from an exclusive finance deal from the British Dental Association for the purchase of dental loupes to help encourage healthy and effective working habits right from the start of their career. The loupes are part of a special new membership benefit offer for students which also includes free membership of the BDA for their final year of study.

Ground breaking companies within the CRO industry

With over 1200 companies within the CRO industry Limdato www.limdato.com is one who is able to utilize cutting edge technology and innovations to ensure complete success for your clinical trial. During the 1970’s the industry was extremely limited to the services it could provide for ...
(613) 686-5745 Cerepotec Pharmalef

Policy Papers Address Payment Reform And Solutions To Challenges Facing Primary Care

New policy papers addressing comprehensive payment reform and solutions to challenges facing primary care physicians have been released by the American College of Physicians (ACP).

AAMS Launches Medevac Helicopter Safety Public Education Campaign

The medical helicopter industry has come under great public scrutiny recently - particularly regarding safety and appropriate usage concerns - but also in relation to questions over foreign-travel access and evacuation-insurance coverage, which have been prompted by the tragic death of award-winning actress Natasha Richardson from a traumatic brain injury after a fall on a Canadian ski slope.

Surgeon Training Found Effective In Breast Cancer Sentinel Lymph Node Trial

Training methods for surgeons who perform breast cancer sentinel lymph node resection were found to be effective in almost 97% of surgeons assessed, according to a new study published online August 24 in the Journal of the National Cancer Institute.

What Clinical Research Is All About

How can researchers prove to the government that a newly-discovered drug or device is safe and effective? This is where the clinical trial comes in. The clinical trial is a research study designed to determine if a new pharmaceutical or medical device is sufficiently safe and effective for ...
(613) 686-5745 Cerepotec Pharmalef

Remote-controlled 'man' Called IStan Trains Healthcare Professionals

A wireless, portable mannequin which can be remote-controlled to talk, sweat, bleed, vomit and have a heart attack is helping put the University of Portsmouth at the forefront of clinical simulation and training in Europe. The mannequin, named iStan, is the most advanced patient simulator on the market and the world's first wireless patient simulator. The university is the first in England to have such cutting edge technology at its fingertips.

Yale Offers Three Science Courses In Free Online Program

Among the undergraduate offerings Yale University is making freely available by Internet access through the Open Yale Courses are three popular science courses in biomedical engineering, physics and astronomy. "Frontiers of Biomedical Engineering," taught by professor W. Mark Saltzman, is newly added to the initial offerings of "Frontiers and Controversies in Astrophysics" by professor Charles Bailyn and "Fundamentals of Physics" by professor Ramamurti Shankar.

Medical Students To Provide Answers To Health Questions Online Via Healia

The American Medical Student Association (AMSA), the nation's oldest and largest independent association for more than 67,000 physicians-in-training, and Healia announced today that medical students and interns/residents from AMSA are now available to answer online health questions from the public for free on Healia Communities (http://communities.healia.com).

The concept of outsourcing should not be new to pharmaceutical companies

The idea of outsourcing clinical trials took a dramatic increase two decades ago and continues to increase at a rapid pace. It is estimated that by 2006 close to 45% of all drug development finances will be allocated to outsourcing to such companies as Limdato, www.limdato.com. Prior to the ...
(613) 686-5745 Cerepotec Pharmalef

Australian Medical Students' Association Welcomes COAG's Investment Into Training The Future Australian Health Workforce

The Federal Government today announced a $1.1 billion health workforce package to be used to fund undergraduate clinical training in public and private hospitals and community settings, train and support clinical training supervisors, and build capital infrastructure including 45 new simulated learning centres.

Health-Care System Leaves Patients, Medicos In The Waiting Room, Australia

The Australian accreditation and registration system for international medical graduates is critically ill and the country needs to create a better system to support overseas health professionals or it will continue to face doctor shortages, according to an academic from The Australian National University.

New Mexico, Other States Implementing Legislation To Ensure Culturally Competent Care

New Mexico is among a "handful of states that are legislating culturally competent care" to ensure that health care providers receive appropriate training, the AP/Las Cruces Sun-News reports. According to the AP/Sun-News, the way a physician enters a room and greets and communicates with patients can be viewed differently by different cultures.

Injury to myelinated axons in the CNS often has a devastating outcome in terms of neuronal loss, with accompanying loss of function.

Damage to the nervous system may result from traumatic injury, such as penetrating or blunt trauma, stroke, or neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), diabetic neuropathy or senile dementia. ...
(613) 686-5745 Cerepotec Pharmalef

Presidential Early Career Award

The White House announced recently that Maura Borrego, an assistant professor in the Virginia Tech College of Engineering's Department of Engineering Education received a Presidential Early Career Award for Scientists and Engineers (PECASE) for the development of methods that will better prepare faculty and graduate students for interdisciplinary research. Borrego's award represents the first one given to an engineer in the area of engineering education research.

AMSA Avant Research Bursary Winners And Applications For 2010

Congratulations to the winners of the 2009 Avant/AMSA Student Research Fellowship: - Flora Poon from Bond University - Tran Nguyen from Flinders University - Daryl Cheng from Monash University - Jun Parker from James Cook University, Cairns - Philip Scott from Ja


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .<br />In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture. <br /><br />One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound. <br />The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material. <br /><br />Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV. <br /><br />This step can be repeated in the future in order to produce more of compound III. <br />Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.<br /><br />Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment. <br /><br />At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.<br />Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.<br /><br />In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.<br />US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. <br /><br />This company is also developing a family of other promising novel chemical compounds. <br /><br />Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans. <br />Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.<br /><br />Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.<br />Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.<br /><br />Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.<br /><br />Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer. <br /><br />Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union. <br />Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.<br /><br />In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.<br />Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market. <br /><br />Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations. <br />Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.<br /><br />They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities. <br /><br />They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.<br />CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008<br /><br />A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838<br /><br />1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.<br /><br />2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.<br /><br />3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.<br /><br />4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.<br /><br />5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.<br /><br />6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.<br /><br />7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.<br /><br />9. The method according to claim 8, wherein said head trauma injury is closed head injury.<br /><br />10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.<br /><br />11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.<br /><br />12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.<br /><br />13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.<br /><br />14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.<br /><br />15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.<br /><br />16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.<br /><br />17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.<br /><br />18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.<br /><br />19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.<br /><br />21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.


Viev all previous articles...

Some Article Feeds provided by MedicalNewsToday.com

More Articles of interest...

RegeneRx Awarded Additional $136,000 From FDA Office Of Orphan Products For Phase II Epidermolysis Bullosa Trial

Regenerx Biopharmaceuticals, Inc. (Amex:Rgn) (www.regenerx.com) announced today that it has been awarded an additional $136,245 from the U.S. Food and Drug Administration's (FDA's) Office of Orphan Products Development for continued development of its Tβ4 drug candidate (RGN-137) for treatment of patients with Epidermolysis Bullosa (EB), a rare and debilitating skin blistering disorder. "We are very pleased to receive this award from the FDA.

Teva's Azilect Use Dramatically Increases In Second-Line Therapy For The Treatment Of Parkinson's Disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report. Most of this increased patient share was driven by growth in the use of Teva's Azilect which is attributed to physicians' growing comfort with the drug and data attesting to its possible neuroprotective (disease-modifying) effects.

MAP Pharmaceuticals Announces Phase 3 Study Of Unit Dose Budesonide In Children With Asthma Did Not Meet Primary Endpoints

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated, when compared with placebo.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity.

The paramount responsibility of Kriger Research Group International CRA-s is to ensure timely subjects recruitment, patient rights, safety and data integrity. In addition to on-site responsibilities each CRA is responsible for site management documentation and follow-up activities ...
(613) 686-5745 Cerepotec Pharmalef

FDA Approves Lilly's Zyprexa For Two Adolescent Indications

The U.S. Food and Drug Administration (FDA) approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old...

Are Lung Disease Patients Using Inhaled Corticosteroid Budesonide At Increased Risk Of Pneumonia?

An article in this week's COPD special issue of The Lancet reports that patients using the inhaled corticosteroid budesonide to treat Chronic Obstructive Pulmonary Disease (COPD) are not at increased risk of pneumonia. In addition, the drug is safe to use in these patients. Those conclusions are contrary to other research findings. Inhaled corticosteroids are prescribed with and without beta-antagonists.

University Of Michigan And University Of Utah Lead Study Of Therapeutic Hypothermia

In the first large-scale study of its kind, researchers at the University of Michigan's C.S. Mott Children's Hospital and the University of Utah will lead a multi-center study to investigate whether hypothermia-lowering body temperature can prevent or reduce brain damage in children deprived of oxygen after a cardiac arrest. The Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials begin this fall.

Clinproxy is on the leading edge of adaptive clinical trials.

Clinproxy, www.clinproxy.com believes that adaptive clinical trials can drastically reduce the cost, time and subject drug exposure of clinical development. Classical clinical trials are planned with extreme dutiful details but once initiated fails to acknowledge that changes often need to be ...
(613) 686-5745 Cerepotec Pharmalef

Herceptin Proven To Benefit Women With HER2 Positive Early Breast Cancer Latest Results From The HERA Study

Study confirms Herceptin's promise of extra years of living cancer free The Breast International Group (BIG) in collaboration with Roche announced that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for one year with Herceptin and followed up for four years.

Genes Affect Weight Loss Drug Effectiveness

A study conducted by researchers at Mayo Clinic shows that obese patients with specific genetic makeup had enhanced response to the weight loss drug sibutramine, while others who lack these genetic factors lost little or no weight. The findings are published in the October issue of Gastroenterology (http://www.gastrojournal.org).

New Long-Term Data Show That Patients Taking AVONEX/(R) For Up To 15 Years Experience Reduced Disability Progression And Improved Quality Of Life

Biogen Idec (NASDAQ: BIIB) announced that data was presented from the ASSURANCE (ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs) study, showing the long-term benefits of AVONEX® (interferon beta-1a IM) therapy in patients with relapsing multiple sclerosis (MS) for up to 15 years.

The World Is Getting Better!

According to Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization, the world is getting better, no matter what critics say. Today’s life expectancy is the highest in human history. In Western countries, we ...
(613) 686-5745 Cerepotec Pharmalef

SPINE Trial Shows That Acupuncture Eases Chronic Low Back Pain

Acupuncture can help people with chronic low back pain feel less bothered by their symptoms and function better in their daily activities, according to the largest randomized trial of its kind, published in the May 11, 2009 Archives of Internal Medicine. But the SPINE (Stimulating Points to Investigate Needling Efficacy) trial raises questions about how the ancient practice actually works.

Sucampo Initiates Pivotal Phase 3 Efficacy Trial Of Lubiprostone For Chronic Idiopathic Constipation In Japan

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), an international biopharmaceutical company, announced that its subsidiary, Sucampo Pharma, Ltd., has initiated enrollment and completed the randomization of the first patient into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan. Under the terms of a license, commercialization and supply agreement Sucampo signed in February 2009 with Abbott Japan Co., Ltd.

Electronic Brachytherapy A Viable Option For Intraoperative Radiation Therapy (IORT)

Clinical experience with the FDA cleared Axxent® Electronic Brachytherapy, eBx(TM), System from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications at the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.

Legal Issues in Clinical Research

Bruce Kriger, CEO of Kriger Research Group International www.kriger.com, leading training institution and clinical research organization told in the interview to our edition that one hundred years ago, any doctor could prepare a new medication without any external approval. Since the ...
(613) 686-5745 Cerepotec Pharmalef


Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .<br />In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture. <br /><br />One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound. <br />The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material. <br /><br />Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV. <br /><br />This step can be repeated in the future in order to produce more of compound III. <br />Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.<br /><br />Cereprotec Inc. www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment. <br /><br />At this moment Cereprotec Inc. www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.<br />Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.<br /><br />In Phase II Cereprotec Inc. www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.<br />US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex. <br /><br />This company is also developing a family of other promising novel chemical compounds. <br /><br />Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans. <br />Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.<br /><br />Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation") www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.<br />Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc. www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.<br /><br />Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.<br /><br />Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer. <br /><br />Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union. <br />Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.<br /><br />In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.<br />Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market. <br /><br />Pharmalef Developments www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations. <br />Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.<br /><br />They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities. <br /><br />They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.<br />CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008<br /><br />A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/20080227838<br /><br />1. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.<br /><br />2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.<br /><br />3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.<br /><br />4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.<br /><br />5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.<br /><br />6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.<br /><br />7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.<br /><br />9. The method according to claim 8, wherein said head trauma injury is closed head injury.<br /><br />10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.<br /><br />11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.<br /><br />12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.<br /><br />13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.<br /><br />14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.<br /><br />15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.<br /><br />16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.<br /><br />17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.<br /><br />18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.<br /><br />19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.<br /><br />20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.<br /><br />21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
HOME . ARTICLESMORE FEATURES .  CONTACT

613-686-5745 Clinical training is not a Scam, you should take training courses that are not a scam. Not a clinical trial scam for training in the clinical trail industry. Clinical Research Associate Courses maybe not a scam but not really a scam you learn alot about Clinic trials. Don't tell me its a scam as I think it does not work. Opinions of Clinical Training seem to say these courses are a scam. This is not truly a scam, scams are not good and clinical trails is not one of them. Take Clinical courses and you won't be scammed. Is Clinical Research Associates Training a scam? 613-686-5745

And a pair of them on 800notes.com. pharmaceutical company you hope to one day work for. Similar to comments bearing the same signature and left elsewhere, it includes talk of defamation, and “offensive or harassing content” removing this blog trinity includes a recruiting agency, a pharma company, and a school

INSTITUTIONS THAT OFFERS A PRACTICAL ORIENTED COURSE IN CLINICAL RESEARCH.ClinfoSource online GCP training courses WARN OF ONE INSTITUTE. STAY AWAY. they will help you find a job in India. certificates courses, numerous spelling and grammar mistakes. Looking for clinical research staff nation-wide to prepare and initiate clinical trials. report a fraud. report this scam. moving forward in their clinical trial as it was approved.Espoir and PharmAlef are a complete and utter fraud

qualified for any clinical trials-related positions, but we highly recommend you get a clinical trials certificate. QA experience: GMP, GLP and GCP certificate through the training and certification  programs accredited by the International Biopharmaceutical Association. Certificate form Kriger and Bachelor's degree in science and clinical research experience preferred. I am still interested in pursuing a career in clinical research. 613-686-5745

http://www.clinicaltoday.com/ . http://pharmaindustrytoday.com/ . http://www.medicaltrainingtoday.com/ . http://medicalnewspress.com . http://medicaldevicesnews.com . http://MedConferencestoday.com . http://regulatoryaffairstoday.com